Pediatric Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
New FDA committee will "provide advice and make recommendations to the commissioner...on matters relating to pediatric therapeutics, pediatric research and any other matter involving pediatrics for which the [FDA] has regulatory responsibility," the agency announces in a final rule slated for publication in the Aug. 2 Federal Register. The 12 voting members will bring experience in pediatric research, subspecialties, statistics and/or bioethics, including a patient organization rep and a "technically qualified member" with consumer interests. FDA also announces the creation of a pediatric ethics subcommittee and requests nominations in separate same-day notices. Formation of the panel is in accordance with the Pediatric Research & Equity Act (1"The Tan Sheet" Dec. 1, 2003, In Brief)...
You may also be interested in...
Pediatric Research Equity Act
S 650 "will provide FDA with additional authority to require pediatric studies of pharmaceutical products when such studies are needed to ensure the safe and effective use of the products in children," agency notes in Nov. 19 release. Bill was presented to President Bush Nov. 21. An amendment linking the expiration of the S 650 to the pediatric exclusivity incentive program remains in the bill (1"The Tan Sheet" Aug. 4, 2003, In Brief)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.